

Erding Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11680340/publications.pdf>

Version: 2024-02-01

25
papers

7,903
citations

361045

20
h-index

580395

25
g-index

25
all docs

25
docs citations

25
times ranked

9242
citing authors

#	ARTICLE	IF	CITATIONS
1	Stimulation of adipogenesis in fibroblasts by PPAR α , a lipid-activated transcription factor. <i>Cell</i> , 1994, 79, 1147-1156.	13.5	3,322
2	AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity. <i>Journal of Biological Chemistry</i> , 1996, 271, 10697-10703.	1.6	1,885
3	Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor α . <i>Current Opinion in Genetics and Development</i> , 1995, 5, 571-576.	1.5	426
4	Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR γ and RXR α . <i>Nucleic Acids Research</i> , 1994, 22, 5628-5634.	6.5	352
5	Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 720-728.	1.3	347
6	Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription Repressor. <i>Journal of Biological Chemistry</i> , 2000, 275, 15254-15264.	1.6	244
7	Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. <i>Cardiovascular Research</i> , 2004, 61, 548-558.	1.8	200
8	Adipocyte differentiation: a transcriptional regulatory cascade. <i>Current Opinion in Cell Biology</i> , 1996, 8, 826-832.	2.6	171
9	Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 89-98.	1.3	142
10	Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 6-9.	2.9	139
11	Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. <i>British Journal of Pharmacology</i> , 2003, 138, 757-766.	2.7	138
12	Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. <i>Cancer Letters</i> , 2002, 188, 127-140.	3.2	88
13	Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 56, 147-155.	0.8	84
14	Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 715-736.	1.5	70
15	Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6631-6634.	2.9	68
16	Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. <i>Vascular Medicine</i> , 2014, 19, 473-482.	0.8	39
17	Tissue Restricted Expression of Two Human Frzbs in Preadipocytes and Pancreas. <i>Biochemical and Biophysical Research Communications</i> , 1998, 247, 287-293.	1.0	38
18	DEF-1, a Novel Src SH3 Binding Protein That Promotes Adipogenesis in Fibroblastic Cell Lines. <i>Molecular and Cellular Biology</i> , 1999, 19, 2330-2337.	1.1	38

#	ARTICLE	IF	CITATIONS
19	Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 306, E150-E156.	1.8	38
20	The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits. <i>PLoS ONE</i> , 2017, 12, e0184049.	1.1	27
21	Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases. <i>Current Opinion in Investigational Drugs</i> , 2003, 4, 1065-75.	2.3	16
22	Recent Patents on Rho Signaling Pathway as Therapeutic Target for Cardiovascular Diseases. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2006, 1, 249-263.	1.5	11
23	In Vivo Imaging of Small Molecular Weight Peptides for Targeted Renal Drug Delivery: A Study in Normal and Polycystic Kidney Diseased Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 786-795.	1.3	8
24	Brain-targeted hypoxia-inducible factor stabilization reduces neonatal hypoxic-ischemic brain injury. <i>Neurobiology of Disease</i> , 2021, 148, 105200.	2.1	8
25	Rapid Isolation of Tissue-Specific Genes from Rat Kidney. <i>Nephron Experimental Nephrology</i> , 2001, 9, 156-164.	2.4	4